162 related articles for article (PubMed ID: 2130925)
61. Fibrinogen Kawaguchi: an abnormal fibrinogen characterized by defective release of fibrinopeptide A.
Matsuda M; Saeki E; Kasamatsu A; Nakamikawa C; Manabe S; Samejima Y
Thromb Res; 1985 Feb; 37(3):379-90. PubMed ID: 3992527
[TBL] [Abstract][Full Text] [Related]
62. Fibrinogen Milano XII: a dysfunctional variant containing 2 amino acid substitutions, Aalpha R16C and gamma G165R.
Bolliger-Stucki B; Lord ST; Furlan M
Blood; 2001 Jul; 98(2):351-7. PubMed ID: 11435303
[TBL] [Abstract][Full Text] [Related]
63. A polymorphism at B beta 448 of fibrinogen identified during structural studies of fibrinogen Baltimore II.
Schmelzer CH; Ebert RF; Bell WR
Thromb Res; 1988 Oct; 52(2):173-7. PubMed ID: 3194892
[No Abstract] [Full Text] [Related]
64. Fibrinogen Baltimore II: congenital hypodysfibrinogenemia with delayed release of fibrinopeptide B and decreased rate of fibrinogen synthesis.
Ebert RF; Bell WR
Proc Natl Acad Sci U S A; 1983 Dec; 80(23):7318-22. PubMed ID: 6580646
[TBL] [Abstract][Full Text] [Related]
65. Fibrinogen Matsumoto II: gamma 308 Asn-->Lys (AAT-->AAG) mutation associated with bleeding tendency.
Okumura N; Furihata K; Terasawa F; Ishikawa S; Ueno I; Katsuyama T
Br J Haematol; 1996 Sep; 94(3):526-8. PubMed ID: 8790154
[TBL] [Abstract][Full Text] [Related]
66. Fibrinogen Seattle releases half the normal amount of fibrinopeptide B.
Branson HE; Schmer G; Theodor I; Pirkle H
Acta Haematol; 1983; 70(4):257-63. PubMed ID: 6414212
[TBL] [Abstract][Full Text] [Related]
67. Fibrinogen Manchester. Detection of a heterozygous phenotype in the intraplatelet pool.
Southan C; Lane DA; Knight I; Ireland H; Bottomley J
Biochem J; 1985 Aug; 229(3):723-30. PubMed ID: 4052020
[TBL] [Abstract][Full Text] [Related]
68. Fibrinogen Claro--another dysfunctional fibrinogen variant with gamma 275 arginine-->histidine substitution.
Steinmann C; Jungo M; Beck EA; Lämmle B; Furlan M
Thromb Res; 1996 Jan; 81(1):145-50. PubMed ID: 8747529
[No Abstract] [Full Text] [Related]
69. Characterization of fibrinogen New York 1. A dysfunctional fibrinogen with a deletion of B beta(9-72) corresponding exactly to exon 2 of the gene.
Liu CY; Koehn JA; Morgan FJ
J Biol Chem; 1985 Apr; 260(7):4390-6. PubMed ID: 3156856
[TBL] [Abstract][Full Text] [Related]
70. Fibrinogen Kyoto II, a new congenitally abnormal molecule, characterized by the replacement of A alpha proline-18 by leucine.
Yoshida N; Okuma M; Hirata H; Matsuda M; Yamazumi K; Asakura S
Blood; 1991 Jul; 78(1):149-53. PubMed ID: 2070049
[TBL] [Abstract][Full Text] [Related]
71. Fibrinogen geneva II: a new congenitally abnormal fibrinogen alpha chain (Gly17Asp) with a review of similar mutations resulting in abnormal knob A.
Casini A; De Maistre E; Casini-Stuppi V; Fontana P; Neerman-Arbez M; de Moerloose P
Blood Coagul Fibrinolysis; 2014 Apr; 25(3):280-2. PubMed ID: 24389539
[TBL] [Abstract][Full Text] [Related]
72. Fibrinogens Kawaguchi and Osaka: an amino acid substitution of A alpha arginine-16 to cysteine which forms an extra interchain disulfide bridge between the two A alpha chains.
Miyata T; Terukina S; Matsuda M; Kasamatsu A; Takeda Y; Murakami T; Iwanaga S
J Biochem; 1987 Jul; 102(1):93-101. PubMed ID: 3667568
[TBL] [Abstract][Full Text] [Related]
73. An abnormal fibrinogen with delayed fibrinopeptide A release.
Lane DA; VanRoss M; Kakkar VV; Bottomley KJ; Dhir K; Holt LP; MacIver JE
Br J Haematol; 1980 Sep; 46(1):89-98. PubMed ID: 7426452
[TBL] [Abstract][Full Text] [Related]
74. Thrombin hydrolysis of an N-terminal peptide from fibrinogen Lille: kinetic and NMR studies.
Zheng Z; Ashton RW; Ni F; Scheraga HA
Biochemistry; 1992 May; 31(18):4426-31. PubMed ID: 1581297
[TBL] [Abstract][Full Text] [Related]
75. Substitution (γ335Trp→Arg) in fibrinogen Fremantle causes diminished γ chain expression and increased sialic acid content.
Brennan SO; Davis RL
Thromb Haemost; 2010 Dec; 104(6):1274-6. PubMed ID: 20838743
[No Abstract] [Full Text] [Related]
76. Abnormal fibrinogens IJmuiden (B beta Arg14----Cys) and Nijmegen (B beta Arg44----Cys) form disulfide-linked fibrinogen-albumin complexes.
Koopman J; Haverkate F; Grimbergen J; Engesser L; Nováková I; Kerst AF; Lord ST
Proc Natl Acad Sci U S A; 1992 Apr; 89(8):3478-82. PubMed ID: 1565641
[TBL] [Abstract][Full Text] [Related]
77. Studies of the structure of canine fibrinogen.
Birken S; Wilner GD; Canfield RE
Thromb Res; 1975 Oct; 7(4):599-610. PubMed ID: 1198547
[No Abstract] [Full Text] [Related]
78. Fibrinogen Lima. A new dysfibrinogenaemia with a high-molecular-weight alpha-chain and effective polymerization.
Arocha-Piñango CL; Rodriguez S; Nagy H; Perez Requejo JL
Blood Coagul Fibrinolysis; 1990 Oct; 1(4-5):561-5. PubMed ID: 2133234
[TBL] [Abstract][Full Text] [Related]
79. On the identity of fibrin(ogen) oligomers appearing during fibrin polymerization.
Henschen A
Adv Exp Med Biol; 1990; 281():49-53. PubMed ID: 2102625
[No Abstract] [Full Text] [Related]
80. The impaired polymerization of fibrinogen Longmont (Bbeta166Arg-->Cys) is not improved by removal of disulfide-linked dimers from a mixture of dimers and cysteine-linked monomers.
Lounes KC; Lefkowitz JB; Henschen-Edman AH; Coates AI; Hantgan RR; Lord ST
Blood; 2001 Aug; 98(3):661-6. PubMed ID: 11468164
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
